Document is current
Any future updates will be listed below
-
Authors
Carbone, David P. https://orcid.org/0000-0003-3002-1921
Ciuleanu, Tudor-Eliade
Schenker, Michael
Cobo, Manuel
Bordenave, Stéphanie
Juan-Vidal, Oscar
Menezes, Juliana
Reinmuth, Niels
Richardet, Eduardo
Cheng, Ying
Mizutani, Hideaki
Felip, Enriqueta
Zurawski, Bogdan
Alexandru, Aurelia
Paz-Ares, Luis
Lu, Shun
John, Thomas
Zhang, Xiaoqing
Mahmood, Javed
Hu, Nan
De, Tuli
Santi, Irene
Penrod, John R.
Yuan, Yong
Lee, Adam
Reck, Martin
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03215706 at ClinicalTrials.govDocuments that mention this clinical trial
1282 Concordance analysis of AI-powered CD8 quantification and automated CD8 topology with manual histopathological assessment across seven solid tumor types
https://doi.org/10.1136/jitc-2022-sitc2022.1282
Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer
https://doi.org/10.1136/jitc-2021-002780
581 Matching-adjusted indirect treatment comparison of tremelimumab + durvalumab + chemotherapy vs pembrolizumab + chemotherapy and nivolumab + ipilimumab + chemotherapy for first-line metastatic NSCLC
https://doi.org/10.1136/jitc-2022-sitc2022.0581
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
Five-year outcomes with first-line (1L) nivolumab + ipilimumab + chemotherapy (N + I + C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA.
https://doi.org/10.1200/jco.2024.42.16_suppl.8560
Tracking the tail
https://doi.org/10.1136/jitc-2020-000971
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial
https://doi.org/10.1136/jitc-2023-008189
First-line (1L) nivolumab (N) + ipilimumab (I) + chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4-y clinical update and outcomes by tumor histologic subtype (THS).
https://doi.org/10.1200/jco.2023.41.17_suppl.lba9023
-
Funding
Funding for this research was provided by:
Bristol Myers Squibb (N/A)
- License Information
